Psychocardiology – the Mind-Body Interaction

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: closed (31 December 2020) | Viewed by 2892

Special Issue Editors


E-Mail Website
Guest Editor
1. Department of Internal Medicine, General Hospital Murska Sobota, Ulica dr. Vrbnjaka 6, SI-9000 Murska Sobota, Slovenia
2. Faculty of Medicine, University of Ljubljana, Vrazov trg 2, SI-1000 Ljubljana, Slovenia
Interests: heart failure; COPD; iron deficiency; cachexia; sarcopenia; frailty; cardiovascular disease

E-Mail Website
Co-Guest Editor
Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Kirrberger Straße, 66421 Homburg/Saar, Germany
Interests: cardiology; heart failure; vascular biology, angiology

E-Mail Website
Co-Guest Editor
Cardiology Department, Institute for Cardiovascular Diseases Dedinje, Belgrade, and Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Interests: heart failure; body wasting; biomarkers; metabolism

Special Issue Information

Dear Colleagues,

Bodily organs are closely interrelated and interdependent. Cardiovascular disease is most common chronic disease worldwide, also responsible for the highest morbidity and mortality burden. Next to direct organ damage with clinical correlates (e.g., stroke with mobility and/or cognitive deficit), heart disease is closely related with patient quality of life, patient perception, and coping with chronic disease. These aspects are frequently neglected in clinical practice, which is primarily focused on the physical rather than psychical implications of the disease.
However, the field of mind–body interaction, psychocardiology in this respect, is an intriguing and interesting field that grows steadily. This issue of the Medicina is dedicated to research in psychocardiology at large, with primary emphasis on patient perception of chronic disease, and interventions which help the patient to cope with the disease. We also welcome contributions in a broader sense of chronic disease and in advanced stage, when body wasting is detected, and the psychological impact of the disease is more pronounced. Finally, systematic and narrative reviews as well as viewpoints to challenge the current boundaries and the potential to advance the field will be considered for publication.

Prof. Mitja Lainscak
Dr. Goran Loncar
Prof. Micheal Böhm
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • heart
  • mind
  • brain
  • chronic disease
  • quality of life
  • sarcopenia
  • cachexia

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

8 pages, 291 KiB  
Brief Report
Somatic Comorbidities and Cardiovascular Safety in Ketamine Use for Treatment-Resistant Depression
by Joanna Szarmach, Wiesław Jerzy Cubała, Adam Włodarczyk and Maria Gałuszko-Węgielnik
Medicina 2021, 57(3), 274; https://doi.org/10.3390/medicina57030274 - 16 Mar 2021
Cited by 7 | Viewed by 2263
Abstract
Background and Objectives: There is evidence for ketamine efficacy in treatment-resistant depression (TRD). Several safety and tolerability concerns arise that some psychotropic agents may provide blood pressure or/and heart rate alterations. The aim of this study is to review blood pressure measurements in [...] Read more.
Background and Objectives: There is evidence for ketamine efficacy in treatment-resistant depression (TRD). Several safety and tolerability concerns arise that some psychotropic agents may provide blood pressure or/and heart rate alterations. The aim of this study is to review blood pressure measurements in course of the treatment with ketamine on treatment refractory inpatients with somatic comorbidities in the course of MDD and BP. Materials and Methods: The study population of 49 patients comprised MDD and BP subjects treated with ketamine registered in the naturalistic observational protocol of treatment-resistant mood disorders (NCT04226963). Results: The conducted analysis showed that among people suffering from hypertension there is a higher increase in systolic blood pressure (RR) after infusion 2 (p = 0.004) than among people who do not suffer from hypertension. Patients with hypertension have a higher increase in diastolic RR compared to those not suffering from hypertension (p = 0,038). Among the subjects with diabetes mellitus, significant differences occurred for infusions 2 (p = 0.020), 7 (p = 0.020), and 8 (p = 0.035) for heart rate (HR), compared to subjects without diabetes mellitus. A higher increase in diastolic RR was noted in the group of subjects suffering from diabetes mellitus (p = 0.010) compared to those who did not. In the hyperlipidemic patients studied, a significantly greater decrease in HR after infusion 5 (p = 0.031) and systolic RR after infusion 4 (p = 0.036) was noted compared to nonpatients. People after a stroke had significantly higher increases in diastolic RR after infusions 4 (p = 0.021) and 6 (p = 0.001) than those who did not have a stroke. Patients suffering from epilepsy had a significantly greater decrease in systolic RR after the 8th infusion (p = 0.017) compared to those without epilepsy. Limitations: The study may be underpowered due to the small sample size. The observations apply to inhomogeneous TRD population in a single-site with no blinding and are limited to the acute administration. Conclusions: This study supports evidence for good safety and tolerability profile for short-term IV ketamine use in TRD treatment. However, risk mitigation measures are to be considered in patients with metabolic and cardiovascular comorbidities. Full article
(This article belongs to the Special Issue Psychocardiology – the Mind-Body Interaction)
Back to TopTop